secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2024-09-20T23:59:59+00:00
Accession:  0001437749-24-029747
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra Therapeutics' MIPLYFFA receives FDA approval as first treatment for Niemann-Pick disease type C
--------------------------------------------------------------------------------

- FDA approved MIPLYFFA (arimoclomol) for NPC in adult and pediatric patients 2 years+; first FDA-approved NPC treatment.
- MIPLYFFA is indicated for use in combination with miglustat for neurological manifestations of NPC.
- Zevra received a rare pediatric disease priority review voucher (PRV) with the approval.
- Launch of AmplifyAssist patient support program; MIPLYFFA expected commercially available in 8-12 weeks.
- Conference call and webcast on Sept 23, 2024 at 8 a.m. ET to discuss approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774924029747/0001437749-24-029747-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774924029747/zvra20240920_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-029747

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer